ABT

Abbott Laboratories [ABT] Stock Forecast

Q: What is Abbott Laboratories stock symbol ?

Abbott Laboratories is a US stock, located in North chicago of Il and trading under the symbol ABT

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ABT Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

ABT has more than 2 years of cash runway (28 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

ABT

Top 10 Correlated Stocks

ABT

In the News

ABT Financial details

Company Rating

Strong Buy

Market Cap

189.33B

Income

5.72B

Revenue

40.11B

Book val./share

22.26

Cash/share

4.2

Dividend

2.12

Dividend %

1.94%

Employees

114K

Optionable

Shortable

Yes

Earnings

17 Apr 2024

P/E

33.06

Forward P/E

PEG

-20.35

P/S

4.72

P/B

4.9

P/C

25.06

P/FCF

37.42

Quick Ratio

Current Ratio

1.64

Debt / Equity

0.39

LT Debt / Equity

0.35

EPS (TTM)

3.3

EPS next Y

EPS next Q

EPS this Y

-16.24%

EPS next Y

EPS next 5Y

EPS last 5Y

9.78%

Revenue last 5Y

4.68%

Revenue Q/Q

0.97%

EPS Q/Q

10.84%

SMA20

-5.76%

SMA50

-3.31%

SMA100

9.41%

Inst Own

61.91%

Inst Trans

0.85%

ROA

ROE

12%

ROC

0.12%

Gross Margin

54%

Oper. Margin

17%

Profit Margin

14%

Payout

62%

Shs Outstand

Shs Float

Target Price

52W Range

89.67-121.64

52W High

-13%

52W Low

+18.28%

RSI

29.39

Rel Volume

1.27

Avg Volume

5.75M

Volume

7.29M

Perf Week

-6.38%

Perf Month

-11.79%

Perf Quarter

12.5%

Perf Half Y

14.25%

Beta

0.74

Volatility

2.2%, 4.23%

Prev Close

-0.59%

Price

105.27

Change

-2.1%

ABT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	18.05	19.52	24.27	24.9	23.05
Net income per share	2.09	2.54	3.98	3.95	3.29
Operating cash flow per share	3.47	4.46	5.93	5.47	4.17
Free cash flow per share	2.54	3.23	4.87	4.45	2.91
Cash per share	2.34	4.03	5.77	5.8	4.18
Book value per share	17.58	18.49	20.17	20.93	22.19
Tangible book value per share	-5.04	-3.12	0.03	2.08	3.64
Share holders equity per share	17.58	18.49	20.17	20.93	22.19
Interest debt per share	11.01	11.36	10.98	10.32	8.94
Market cap	153.57B	194.13B	249.81B	192.46B	191.52B
Enterprise value	168.6B	206.94B	259.02B	200.3B	200.5B
P/E ratio	41.65	43.19	35.33	27.76	33.47
Price to sales ratio	4.81	5.61	5.8	4.41	4.78
POCF ratio	25.03	24.57	23.72	20.09	26.38
PFCF ratio	34.14	33.91	28.89	24.66	37.86
P/B Ratio	4.94	5.92	6.98	5.25	4.96
PTB ratio	4.94	5.92	6.98	5.25	4.96
EV to sales	5.28	5.98	6.01	4.59	5
Enterprise value over EBITDA	25.32	27.26	24.1	18.73	18.94
EV to operating cash flow	27.48	26.19	24.59	20.91	27.61
EV to free cash flow	37.48	36.15	29.95	25.67	39.63
Earnings yield	0.02	0.02	0.03	0.04	0.03
Free cash flow yield	0.03	0.03	0.03	0.04	0.03
Debt to equity	0.61	0.6	0.53	0.48	0.39
Debt to assets	0.28	0.27	0.25	0.24	0.2
Net debt to EBITDA	2.26	1.69	0.86	0.73	0.85
Current ratio	1.44	1.72	1.85	1.63	1.64
Interest coverage	7.87	10.71	17.19	22.3	10.17
Income quality	1.66	1.76	1.49	1.38	1.27
Dividend Yield	0.01	0.01	0.01	0.02	0.02
Payout ratio	0.62	0.57	0.45	0.48	0.62
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.08	0.07	0.06	0.07	0.07
Intangibles to total assets	0.59	0.53	0.48	0.45	0.44
Capex to operating cash flow	-0.27	-0.28	-0.18	-0.19	-0.3
Capex to revenue	-0.05	-0.06	-0.04	-0.04	-0.05
Capex to depreciation	-0.54	-0.65	-0.53	-0.54	-0.68
Stock based compensation to revenue	0.02	0.02	0.01	0.02	0.02
Graham number	28.72	32.48	42.52	43.15	40.52
ROIC	0.08	0.09	0.13	0.13	0.1
Return on tangible assets	0.13	0.13	0.18	0.17	0.14
Graham Net	-14.83	-14.15	-12.1	-10.05	-10.86
Working capital	4.8B	8.53B	11.13B	9.74B	8.83B
Tangible asset value	-8.92B	-5.53B	54M	3.65B	6.33B
Net current asset value	-20.92B	-19.1B	-14.93B	-12.31B	-11.72B
Invested capital	0.61	0.6	0.53	0.48	0.39
Average receivables	5.3B	5.92B	6.45B	7.68B	7.72B
Average payables	3.11B	3.6B	4.18B	4.51B	4.45B
Average inventory	4.06B	4.66B	5.08B	5.67B	6.37B
Days sales outstanding	62.07	67.65	54.97	74.26	59.74
Days payables outstanding	89.71	96	86.8	87.85	87.21
Days of inventory on hand	119.06	121.93	101.54	117.71	133.41
Receivables turnover	5.88	5.4	6.64	4.92	6.11
Payables turnover	4.07	3.8	4.21	4.15	4.19
Inventory turnover	3.07	2.99	3.59	3.1	2.74
ROE	0.12	0.14	0.2	0.19	0.15
Capex per share	-0.93	-1.23	-1.06	-1.01	-1.27

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	5.81	5.6	5.73	5.83	5.91
Net income per share	0.59	0.76	0.79	0.83	0.92
Operating cash flow per share	1.34	0.66	0.69	1.08	1.75
Free cash flow per share	0.99	0.44	0.4	0.76	1.32
Cash per share	5.85	5.84	4.69	4.05	4.2
Book value per share	21.11	42.61	21.36	21.56	22.26
Tangible book value per share	2.1	2.65	2.48	2.95	3.65
Share holders equity per share	21.11	42.61	21.36	21.56	22.26
Interest debt per share	10.23	9.72	9.77	9.03	8.74
Market cap	190.79B	176.37B	189.73B	168.39B	190.87B
Enterprise value	198.63B	183.26B	198.74B	177.21B	199.85B
P/E ratio	46.17	33.45	34.5	29.32	29.94
Price to sales ratio	18.91	18.09	19.02	16.6	18.64
POCF ratio	82.03	154.3	157.72	89.71	62.83
PFCF ratio	111.18	231.15	272.61	127.86	83.6
P/B Ratio	5.2	2.38	5.1	4.49	4.94
PTB ratio	5.2	2.38	5.1	4.49	4.94
EV to sales	19.68	18.8	19.92	17.47	19.51
Enterprise value over EBITDA	106.33	73.78	80.69	68.34	74.65
EV to operating cash flow	85.39	160.33	165.21	94.41	65.78
EV to free cash flow	115.75	240.18	285.55	134.56	87.54
Earnings yield	0.01	0.01	0.01	0.01	0.01
Free cash flow yield	0.01	0	0	0.01	0.01
Debt to equity	0.48	0.23	0.45	0.41	0.39
Debt to assets	0.24	0.23	0.23	0.22	0.2
Net debt to EBITDA	4.19	2.77	3.66	3.4	3.35
Current ratio	1.63	1.63	1.64	1.74	1.64
Interest coverage	19.76	10.97	10.46	10.66	7.93
Income quality	2.25	0.87	0.87	1.31	1.91
Dividend Yield	0	0.01	0	0.01	0
Payout ratio	0.8	0.68	0.65	0.62	0.56
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.07	0.07	0.07	0.07	0.07
Intangibles to total assets	0.45	0.45	0.45	0.45	0.44
Capex to operating cash flow	-0.26	-0.33	-0.42	-0.3	-0.25
Capex to revenue	-0.06	-0.04	-0.05	-0.06	-0.07
Capex to depreciation	-0.76	-0.47	-0.63	-0.68	-0.93
Stock based compensation to revenue	0.01	0.03	0.01	0.01	0.01
Graham number	16.8	26.94	19.49	20.01	21.46
ROIC	0.02	0.02	0.03	0.03	0.03
Return on tangible assets	0.03	0.03	0.03	0.04	0.04
Graham Net	-10.14	-9.86	-10.34	-9.95	-10.9
Working capital	9.74B	9.74B	9.16B	9.62B	8.83B
Tangible asset value	3.65B	4.62B	4.31B	5.14B	6.33B
Net current asset value	-12.31B	-11.34B	-12.45B	-11.73B	-11.72B
Invested capital	0.48	0.23	0.45	0.41	0.39
Average receivables	7.64B	8.53B	8.33B	8.72B	7.77B
Average payables	4.37B	4.61B	4.41B	4.09B	4.13B
Average inventory	5.95B	6.17B	6.52B	6.76B	6.61B
Days sales outstanding	79.21	75.46	76.48	79.57	57.69
Days payables outstanding	90.27	96.11	84.54	77.41	77.57
Days of inventory on hand	120.96	128.78	137.94	129.97	118.66
Receivables turnover	1.14	1.19	1.18	1.13	1.56
Payables turnover	1	0.94	1.06	1.16	1.16
Inventory turnover	0.74	0.7	0.65	0.69	0.76
ROE	0.03	0.02	0.04	0.04	0.04
Capex per share	-0.35	-0.22	-0.29	-0.32	-0.44

ABT Dividend History

ABT Frequently Asked Questions

What is Abbott Laboratories stock symbol ?

Abbott Laboratories is a US stock , located in North chicago of Il and trading under the symbol ABT

What is Abbott Laboratories stock quote today ?

Abbott Laboratories stock price is $105.27 today.

Is Abbott Laboratories stock public?

Yes, Abbott Laboratories is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 5.75M
Market Capitalization 189.33B
Employee 114K
CEO Mr. Robert B. Ford
Headquarters North Chicago,IL,US
IPO Date 1980-03-17
Website https://www.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.